Clinical Trial Update: Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating nitazoxanide for post-exposure prophylaxis of COVID-19 and other viral respiratory illnesses in elderly long-term care residents was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Viral Respiratory Infections

Drugs mentioned

• Nitazoxanide (Alinia) (nitazoxanide)

Snippet

Sponsor: Romark Laboratories L.C. | Conditions: COVID-19, Viral Respiratory Illnesses | Phase 3 | Status: TERMINATED | Results posted: 2024-07-08